Status:

ACTIVE_NOT_RECRUITING

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Kenya Medical Research Institute

Conditions:

Human Immunodeficiency Virus

Human Papillomavirus

Eligibility:

FEMALE

25+ years

Phase:

PHASE2

Brief Summary

The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to impr...

Detailed Description

WLWH face up to six times increased risk of cervical cancer, as a result, cervical cancer is a leading cause of death in this population. Cervical cancer is caused by persistent infection with the hum...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age 25 years or older
  • Known HIV seropositive status
  • On antiretroviral therapy for \> 90 days prior to enrollment
  • Weight ≥50 Kg at study entry\*
  • Positive HPV screening test and within 4-8 weeks of thermal ablation
  • Ability to provide informed consent
  • Planning to stay within the study locale during the duration of the study (24 weeks)
  • Agreement to use contraception (barriers or hormonal) if of childbearing age through week 6 of the study
  • Exclusion Criteria
  • Current pregnancy or breastfeeding status
  • Current or past history of invasive cervical cancer
  • History of total hysterectomy
  • Currently receiving systemic chemotherapy or radiation therapy for another cancer
  • Current use of systemic immunosuppressants or steroids (\>10 mg of prednisone or equivalent)
  • Current use of efavirenz antiretroviral therapy, phenytoin, carbamazepine, and rifampin
  • Have medical comorbidity that, in the opinion of the investigator, would interfere with study participation
  • Prior chemotherapy within 30 days prior to day 1 of study treatment
  • Male at birth

Exclusion

    Key Trial Info

    Start Date :

    January 22 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 8 2026

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT06519994

    Start Date

    January 22 2025

    End Date

    April 8 2026

    Last Update

    December 17 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building

    Kisumu, Kenya, 614-40100

    Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya | DecenTrialz